HIV-2 Infection
Conditions
Keywords
virus, HIV, cohort
Brief summary
The HIV2 study is an open cohort of prospective, multicentric, national observation. The main objective is to study HIV-2 infection in adult patients followed in France.
Detailed description
The secondary objectives are : * Describe the epidemiological and clinical characteristics of participants infected with HIV-2, and the immuno-virological characteristics of the infection. * To study the clinical and immunological progression of HIV-2 infection and the prognostic factors of this evolution. * Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection. * Allow an evaluation of the care practices of participants followed in French hospitals * Provide a bank of clinical-biological data and samples allowing the performance of virological and / or immunological studies on HIV-2 infection. The follow-up of the participants is different according to the therapeutic status of the participants, naive of antiretroviral treatment or already treated with antiretrovirals.
Interventions
DRUGAntiretroviral
Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
Sponsors
ANRS, Emerging Infectious Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-2 infection only, diagnosed by ELISA, confirmed by Western-Blot test, * Follow-up in consultation or hospitalization in one of the investigating centers, * Age greater than or equal to 18 years, * Prolonged follow-up possible, residence in France planned for at least one year, * Consent to participate, * Long-term medical care possible for the participant, or by medical aid (AME), or declaration of obtaining AME at the time of inclusion.
Exclusion criteria
* HIV-1 infection * Double HIV-1 + HIV-2 seropositivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study HIV-2 infection rate in adult patients followed in France | At the baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The epidemiological parameters and progression of patients infected with HIV-2 evaluate by a questionnaire | Up to 25 years | Every 6 months |
| The rate of immuno-virological charge of the infection evaluate by serology samples | Up to 25 years | Every 6 months |
| The clinical progression of patients infected HIV-2 evaluate by samples: biological examinations | Up to 25 years | Every 6 months |
| Pourcentage of response to antiretroviral treatment evaluate by serology samples | Up to 25 years | — |
| Pourcentage of good management practices of patients followed in French hospitals evaluate by results | Up to 25 years | During the procedure |
| Pourcentage of patient with HIV-2 | Up to 25 years | The prognostic factors of patient evolution are evaluate by biological samples |
Countries
France
Contacts
Primary ContactSophie Matheron, Pr, MD
Backup ContactJulie Longobardi
Outcome results
None listed